Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on May 10, 2022. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on director compensation and appointment details.
- Director Cash Compensation: $40,000 per year.
- Equity Grant: 44,000 shares via a 10-year non-qualified stock option.
- Exercise Price: Equal to the closing price on the Grant Date (May 18, 2022).
- Vesting Schedule: Equal annual amounts over three years, with the first one-third vesting on March 18, 2023.
Material Changes
The Board of Directors increased its size from seven to eight members. David L. Johnson, M.B.A., was appointed as a Class II director effective May 11, 2022. He was not immediately appointed to any Board committees.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies were disclosed in this report other than standard indemnification agreements entered into by the new director.
Investor Verification Checklist
- Verify the closing stock price on May 18, 2022, to determine the exercise price of the 44,000 share option grant.
- Review the Company's 2021 Equity Incentive Plan to understand the full terms of the equity awards.
- Confirm the total number of directors on the Board is now eight.
- Check subsequent filings for any committee assignments for Mr. Johnson.